About 200 reports

  • SCD Patients with Chronic Anaemia, total (000s)
  • REFERENCES

SCD Patients with Asthma, total (##s) Table ##.

  • Blood Disease
  • Pathology

It is also being evaluated for the treatment of Crohn' s disease, psoriatic arthritis, and asthma.

  • Blood Disease
  • AbbVie Inc.
  • Amgen Inc.
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • 7.1.3 Business Strategy

Pulmonary Embolism Diagnostics Market: Size, Trends & Forecasts (2017-2021) APRIL 2017 ##.

  • Blood Disease
  • Cardiovascular Disease
  • World
  • Cyclopharm Limited
  • Lifesciences Limited

Xolair (omalizumab) is marketed by Genentech and Novartis to treat allergic asthma and chronic idiopathic urticaria (a chronic skin condition).

  • Blood Disease
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited
  • Hematological Disorders Therapeutics Market,
  • 7.3.3.1 Overview of Pipeline Programs Targeting Complement

The mAb IL##RA antagonist therapy is in Phase II development for HES, and also at the Pre-registration stage for asthma and Phase III for chronic obstructive pulmonary disorder (COPD).

  • Blood Disease
  • World
  • Acceleron Pharma, Inc.
  • La Jolla Pharmaceutical Company
  • Omeros Corporation

IT IS A SMALL MOLECULE, IRREVERSIBLE INHIBITOR OF FACTOR XIA, YET IT ALSO ACTS AS A SELECTIVE BETA-LACTAM TRYPTASE INHIBITOR-HAVING POTENTIAL USE FOR THE TREATMENT OF ALLERGIC ASTHMA.

  • Blood Disease
  • Boehringer Ingelheim GmbH
  • Janssen Biotech, Inc.
  • Pfizer Inc.
  • Portola Pharmaceuticals, Inc.

You can easily book an appointment with one online.

  • Blood Disease
  • Japan
  • Chugai Pharmaceutical Co., Ltd.
  • Kissei Pharmaceutical Co., Ltd.
  • Kyowa Hakko Kirin Co., Ltd.

Total, serious adverse events Blood and lymphatic system disorders ##/ ##(##. ##%) ##/ ##(##. ##%) ##/ ##(##. ##%) BONE MARROW FAILURE ##/ ##(##. ##%) ##/ ##(##. ##%) ##/ ##(##. ##%) FEBRILE NEUTROPENIA ##/ ##(##. ##%) ##/ ##(##. ##%) ##/ ##(##. ##%)

  • Blood Disease
  • Clinical Trial
  • Leukemia
  • Therapy
  • World
  • Coagulation Factor XIII
  • PLASMA-DERIVED PRODUCTS AND ITS APPLICATIONS IN CRITICAL CARE

The plasma fractionation market is projected to reach to USD 29.50 billion by 2023 from an estimated USD 21.23 billion in 2018. The growing geriatric population across the globe, increasing use of immunoglobulins in various therapeutic areas, growing prevalence of respiratory diseases and uptake of alpha-1-antitrypsin, and increase in plasma...

  • Blood Disease
  • North America
  • United States
  • Market Size
  • Grifols, S.A.

Asthma ## Deep Vein Thrombosis ## Diabetes Mellitus ## IgE-mediated Allergic Disorders ## Inflammatory Diseases ## Lipid Disorder ## Sepsis ## Indication No of Products Abionic SA - Pipeline Analysis Overview ABIONIC SA - KEY FACTS ABI

  • Blood Disease
  • Switzerland
  • United States
  • World
  • Abionic SA

Drivers and their Impact Exemption from Pricing Constraints Incentives for Developing Orphan Drugs ## ## ## ## ## Hospitals Low Low ## ## ## ## ## High High Low Low ## ## ## ## ## High High ROI High Pharmaceutical Stores Low Low ## ## ## ## ## High High ## ## ## ## ## Low High

  • Blood Disease
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.

IT AFFECTS ## IN ##, ## TO ## IN ##, ## BIRTHS.

  • Blood Disease
  • Clinical Trial
  • Hospital
  • Nucleic Acid
  • GlobalData's company
  • BMS-262084 - DRUG PROFILE
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Dormant Products

Similarly, the universities portfolio in Preclinical stages comprises ## molecules, respectively.

  • Blood Disease
  • Therapy
  • United States
  • World
  • Bristol-Myers Squibb Company
  • ATHEROSCLEROSIS - PIPELINE BY INSPYR THERAPEUTICS INC, H2 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018 (CONTD..3), H2 2018

It is also developing new approaches to the treatment of asthma.

  • Blood Disease
  • United States
  • Company
  • Product Initiative
  • Esperion Therapeutics, Inc.
  • BMS-262084 - DRUG PROFILE
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Dormant Products

Similarly, the universities portfolio in Discovery stages comprises ## molecules, respectively.

  • Blood Disease
  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018 (CONTD..3), H1 2018

SUGGEST THAT LC##-## COULD BE A POTENTIAL THERAPEUTIC FOR BRONCHIAL ASTHMA.

  • Blood Disease
  • Digestive System Disorder
  • United States
  • Product Initiative
  • Esperion Therapeutics, Inc.
  • Follicular Lymphoma
  • DORMANT PRODUCTS, H1 2018 (CONTD..2), H1 2018

The study lasted for ## year.

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Dormant Products, H1 2018

The Phase ## study will recruit approximately ## healthy participants and will be conducted at one center in Belgium.

  • Blood Disease
  • Clinical Trial
  • Therapy
  • United States
  • Product Initiative

It effects from ## in ## to ## in 2000 people worldwide.

  • Blood Disease
  • Clinical Trial
  • Prostate Cancer
  • United States
  • GlobalData's company
  • Dormant Products, H2 2018
  • Territory

The molecules developed by companies in Phase III, Preclinical, Discovery and Unknown stages are ##, ##, ## and ## respectively.

  • Blood Disease
  • Hospital
  • Therapy
  • United States
  • Product Initiative
  • DORMANT PRODUCTS, H2 2018 (CONTD..2), H2 2018

Invectys SA is developing INVAC-##.

  • Blood Disease
  • Cancer
  • Lung Cancer
  • Therapy
  • Geron Corporation
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2017
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017 (CONTD..3), H2 2017

It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases.

  • Blood Disease
  • Cancer
  • Pharmaceutical
  • Therapy
  • Incyte Corporation
  • Deal Type

Regeneron also has various product candidates under clinical development for treating asthma, pain, cancer, atopic dermatitis and infectious diseases.

  • Blood Disease
  • Pharmaceutical
  • RNA Interference
  • Therapy
  • Alnylam Pharmaceuticals, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY UNIVERSITIES/INSTITUTES, H2 2018

Lignamed LLC was awarded phase I STTR grant award of USD ##, ## from National Institutes of Health to develop LGM## as a treatment for asthma.

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

ADVANTAGES ##.

  • Blood Disease
  • United States
  • Roche Group
  • SteadyMed Ltd.
  • West Pharmaceutical Services, Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018 (CONTD..4), H1 2018

It is also developing new approaches to the treatment of asthma.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation
  • PRODUCTS UNDER DEVELOPMENT BY UNIVERSITIES/INSTITUTES, H1 2018
  • RADIATION TOXICITY (RADIATION SICKNESS, ACUTE RADIATION SYNDROME) - PIPELINE BY FIRSTSTRING RESEARCH INC, H1 2018

Lignamed LLC was awarded phase I STTR grant award of USD ##, ## from National Institutes of Health to develop LGM## as a treatment for asthma.

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE - PIPELINE BY ASTRAZENECA PLC, H2 2018
  • VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE - PIPELINE BY ASKLEPION PHARMACEUTICALS LLC, H2 2018

It is also developing new approaches to the treatment of asthma.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.

The company" s pipeline candidate HX-## is developed to treat diabetic neuropathy and allergic asthma.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Athersys, Inc.

Deal Rationale Cal-## is under development for the treatment of HIV-## Infection.

  • Blood Disease
  • Pharmaceutical
  • Vaccine
  • United States
  • CSL Limited